Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environmentDetection and measurement of surface contamination by multiple antineoplastic drugs using multiplex bead assayDetection of 5-fluorouracil surface contamination in near real timeExposure to hazardous drugs in healthcare: an issue that will not go awayReduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer deviceSafe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingDrug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical dataEvolution of ramucirumab in the treatment of cancer - A review of literatureCeritinib: A primer for pharmacists.Antineoplastic agents and thrombotic microangiopathy.A review in the treatment of oncologic emergencies.Does applying technology throughout the medication use process improve patient safety with antineoplastics?Adherence with capecitabine: A population-based analysis based on prescription refill data.Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy.Chemotherapy induced diarrhea.Phase I study of docetaxel and topotecan in patients with advanced malignancies.Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration.Evaluation of a clinical scoring scale to direct early appropriate therapy in heparin-induced thrombocytopenia.Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.Oxaliplatin-induced acute thrombocytopenia.Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors.Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma.Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment.Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience.Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.Romiplostim resistance in secondary failure of platelet recovery.Authorising bortezomib treatment prior to reviewing haematology results: a step toward home administration.Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review.Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.Activity of single-agent decitabine in atypical chronic myeloid leukemia.Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.
P1433
Q23914149-93082137-F011-4ACA-8B8F-54DF8066E02BQ23914798-916502DE-8297-4EA4-8060-44315935EFCFQ23914799-39F9AB26-1C79-485F-B816-ABAA348C13CDQ23914914-4190DEFD-FFEB-4AB0-B8A5-F468B36BA512Q23919324-172C768B-6828-43AA-9A02-430DEF321F94Q23923997-0E3FA19D-DCC3-4AC4-918A-988216B3358FQ28084970-8F47A777-B411-4E39-8818-E528C0F7A99EQ28276412-866E25D7-58BC-4531-AEA4-152D6CDD2DFBQ30244613-9926886F-907C-4D3F-91FB-3049C9B2273DQ30251919-003FCFE6-296E-4184-AB49-21DBEDC05540Q30252082-9358C2BC-CF8D-42EA-9BDB-7BE1A4929C25Q30457252-D8186107-F9C0-4213-BEE7-BD6219379225Q31140272-0CDCFCCA-4353-40FA-B814-13E7307425F9Q33158720-3E22E123-04A1-45F8-B194-464D8C498395Q33233193-5DF65A31-6A5C-4770-8FD1-593D1E1E89A9Q33259460-DCBC8A1A-B241-40A0-9A96-1D60991AAB45Q33307663-AE607684-E7D6-4598-803D-462A3804D221Q33370768-E3568513-5347-48B2-B1A5-8EEB0DABCDC7Q33384996-22E64352-1921-4376-B5B5-340A8B10AAD5Q33384998-75BBFA52-357F-4FDB-B6D0-7777956D38D1Q33385898-0303420E-0B3F-4EA0-970C-FA19BB708503Q33386661-59EEE764-CB98-44E3-80FD-B8F84745BDBEQ33387037-7A32CC4B-B755-4E95-B30D-1412A50BB929Q33391330-F90B753D-F1DC-4449-8531-A3AFFA738153Q33391777-D2AEAF48-C2C4-4585-827D-9301F815C211Q33396455-DCA59EA6-07B7-4F68-A1E8-B8C6DB52D11FQ33399863-B9E2D260-4959-471F-BBA8-CBE0E076398BQ33403648-C40897F7-EFC8-4C44-BE2F-D92A3568665DQ33405119-EFB4703F-6EDA-4A18-A800-0C737F124841Q33405121-3927E013-BFA2-494A-9416-3223455F26B1Q33411100-44E5EA6F-5D7D-4947-9541-2AC5E87B5AC4Q33413179-67B5588D-8169-4504-9C5A-73A8C5DA957CQ33414335-0E5FD473-9412-4190-B532-C8DDE4C80B3CQ33416681-CFD45F60-1447-4950-A57F-356ECA9C1C1CQ33416738-7418C0AC-2141-4BB5-91CB-7F263214F572Q33419794-B71D65EA-A2C5-4195-B49C-8A01F62FDD86Q33425922-FF2F4CA3-96FD-43F8-AE6B-EC9F83BF8AC5Q33426772-AE0A0906-F233-47BB-A2F1-F427D0E297E6Q33429346-EFBAAF3B-A1CD-4AD7-BFF8-FB178FD31CC4Q33429840-D2C5DE10-BA26-4611-8505-BC396578D7E2
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van SAGE Publications
@nl
wissenschaftliche Fachzeitschrift
@de
مجلة
@ar
वैज्ञानिक पत्रिका
@hi
name
Journal of Oncology Pharmacy Practice
@ast
Journal of Oncology Pharmacy Practice
@da
Journal of Oncology Pharmacy Practice
@en
Journal of Oncology Pharmacy Practice
@es
Journal of Oncology Pharmacy Practice
@fi
Journal of Oncology Pharmacy Practice
@fr
Journal of Oncology Pharmacy Practice
@it
Journal of Oncology Pharmacy Practice
@nb
Journal of Oncology Pharmacy Practice
@nl
Journal of Oncology Pharmacy Practice
@nn
type
label
Journal of Oncology Pharmacy Practice
@ast
Journal of Oncology Pharmacy Practice
@da
Journal of Oncology Pharmacy Practice
@en
Journal of Oncology Pharmacy Practice
@es
Journal of Oncology Pharmacy Practice
@fi
Journal of Oncology Pharmacy Practice
@fr
Journal of Oncology Pharmacy Practice
@it
Journal of Oncology Pharmacy Practice
@nb
Journal of Oncology Pharmacy Practice
@nl
Journal of Oncology Pharmacy Practice
@nn
prefLabel
Journal of Oncology Pharmacy Practice
@ast
Journal of Oncology Pharmacy Practice
@da
Journal of Oncology Pharmacy Practice
@en
Journal of Oncology Pharmacy Practice
@es
Journal of Oncology Pharmacy Practice
@fi
Journal of Oncology Pharmacy Practice
@fr
Journal of Oncology Pharmacy Practice
@it
Journal of Oncology Pharmacy Practice
@nb
Journal of Oncology Pharmacy Practice
@nl
Journal of Oncology Pharmacy Practice
@nn
P243
P3181
P1055
P1058
P1144
P1156
P1160
J. Of Oncology Pharm. Practice
P123
P1277
P1476
The Journal of Oncology Pharmacy Practice
@en
P236
P243
P3181
P407
P571
1995-01-01T00:00:00Z